GEIST:UPC Searchengine

UPC-CFI-0001509/2025

GlaxoSmithKline Biologicals SA v. C.P. Pharmaceuticals International C.V., Pfizer Export B.V., Pfizer B.V., Pfizer Manufacturing Belgium N.V., Pfizer Service Company B.V./S.r.l., Pfizer S.A./N.V., Pfizer Luxembourg SARL, Pfizer Inc., Pfizer Corporation Austria Gesellschaft m.b.H, Pfizer ApS, Pfizer Oy, Pfizer S.A.S., Pfizer Pharma GmbH, Pfizer S.r.l., Laboratórios Pfizer, Lda., Pfizer Romania S.R.L., Pfizer AB, Pfizer, spol. S.r.o., Pfizer Hellas A.E., Pfizer, S.L., Pfizer Croatia d.o.o., Pfizer Gyógyszerkereskedelmi Kft., Pfizer Polska Sp. Z.o.o., Pfizer Trading Polska Sp. Z.o.o., Pfizer AG, Pfizer AS, BioNTech SE, BioNTech Europe GmbH, BioNTech Manufacturing GmbH, BioNTech Manufacturing Marburg GmbH

Datum
2026-11-10
Kammer
The Hague (NL) Local Division
Verfahrensart
Counter claim for revocation
Sprache
EN

Metadaten

Fall-IDUPC-CFI-0001509-2025-b96e3a1e2a87
AktenzeichenUPC-CFI-0001509/2025
RegisterzeichenUPC-CFI-0001509/2025
Entscheidungsreferenz
Schlagwörter
Leitsätze

Dokumente und Volltext

Textextraktion: pypdf | Seiten: 73

1 The Hague - Local Division UPC_CFI_620/2025 UPC_CFI_1509/2025 UPC_CFI_1511/2025 Decision of the Court of First Instance of the Unified Patent Court delivered on 10 November 2026 HEADNOTES 1. Patent on liposomes for RNA vaccine delivery held (mostly) valid and infringed. 2. The claimed range of pKa 5.0-6.8 is not to be interpreted as containing rigid cut-off limits in the present case. The claim, which includes a specific measurement method, should be read together with the description which contains a reference to a measurement imprecision for this method of +-0.2 pKa units. 3. The patent is entitled to partial priorities. The patent may rely on P1 (US830) for the range of pKa 5.0-6.7 (so partially according to G1/15), with date 6 July 2010 and for the claim with upper pKa limit 6.8 on P ...